Generic Name and Formulations:
Tobramycin 0.3%; oph. soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for TOBREX:
Susceptible infections of conjunctiva and cornea.
Adults and Children:
<2mos: not established. ≥2mos: Mild to moderate infections: 1–2 drops every 4hrs or ½ inch of ointment 2–3 times daily. Severe infections: 2 drops every hr or ½ inch of ointment every 3–4hrs until improvement; then reduce before discontinuing.
Discontinue if superinfection or hypersensitivity occurs. Remove contact lenses before using. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant systemic aminoglycosides: monitor levels.
Lid itching/swelling, conjunctival erythema, hypersensitivity; oint: may retard corneal healing.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds